GB840870A - Improvements in or relating to insulin preparations - Google Patents

Improvements in or relating to insulin preparations

Info

Publication number
GB840870A
GB840870A GB22705/58A GB2270558A GB840870A GB 840870 A GB840870 A GB 840870A GB 22705/58 A GB22705/58 A GB 22705/58A GB 2270558 A GB2270558 A GB 2270558A GB 840870 A GB840870 A GB 840870A
Authority
GB
United Kingdom
Prior art keywords
insulin
solution
exceed
zinc
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB22705/58A
Inventor
Jorgen Schlichtkrull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Terapeutisk Laboratorium AS
Original Assignee
Novo Terapeutisk Laboratorium AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Terapeutisk Laboratorium AS filed Critical Novo Terapeutisk Laboratorium AS
Publication of GB840870A publication Critical patent/GB840870A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A quick-acting insulin preparation is prepared by dissolving insulin derived from pig pancreas in an aqueous injectable medium having or being given a pH value of between 7 and 8. A solution of a compound of one or more metals that are prerequisite to the crystallization of insulin, i.e. zinc, cobalt, nickel or cadmium may be added providing the total metal content of the solution does not exceed about 13 X A X 10-13 milli equivalents per litre, A being the number of international units of insulin per millilitic. Buffering agents, for example, phosphate, citrate, acetate, borate, maleate, diethyl barbiturate and glycerol buffers may also be present. If the buffer used is capable of forming complexes with the metal ions present, the amount of metal compound added may exceed the above stated amount providing the free metal ions in solution do not exceed the limit. An example given is the preparation of an 0.02M aqueous solution of sodium acetate containing per litre 1.74 gms. (40,000 international units) of crystalline insulin derived from pig pancreas and containing about 0.7% zinc, 2 ml. N hydrochloric acid, 1 gm. methyl-p-hydroxybenzoate, 1.4% by weight NaCl, the pH being adjusted to 7.3 to 7.5 with sodium hydroxide.
GB22705/58A 1957-08-03 1958-07-15 Improvements in or relating to insulin preparations Expired GB840870A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK840870X 1957-08-03

Publications (1)

Publication Number Publication Date
GB840870A true GB840870A (en) 1960-07-13

Family

ID=8153224

Family Applications (1)

Application Number Title Priority Date Filing Date
GB22705/58A Expired GB840870A (en) 1957-08-03 1958-07-15 Improvements in or relating to insulin preparations

Country Status (3)

Country Link
CY (1) CY217A (en)
GB (1) GB840870A (en)
MY (1) MY6100048A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118355A1 (en) 2013-02-04 2014-08-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9839675B2 (en) 2013-02-04 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014118355A1 (en) 2013-02-04 2014-08-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3747426A1 (en) 2013-02-04 2020-12-09 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10610595B2 (en) 2014-01-09 2020-04-07 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899191A (en) * 2014-01-09 2016-08-24 赛诺菲 Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899191B (en) * 2014-01-09 2020-06-16 赛诺菲 Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
CY217A (en) 1961-03-27
MY6100048A (en) 1961-12-31

Similar Documents

Publication Publication Date Title
GB840870A (en) Improvements in or relating to insulin preparations
JPS5642970A (en) Redox battery
GB1385086A (en) Insulin product
GB718574A (en) Bath for the deposit of gold alloys by electroplating
GB1038678A (en) Compounds having an adrenocorticotrophic hormone action and process for their manufacture
GB907303A (en) Improvements in or relating to the production of semi-conductor devices
GB1310610A (en) Electro-less nickel plating compositions
GB1395502A (en) Herbicidal compositions
GB835638A (en) Insulin crystal suspensions having a protracted effect
GB1247980A (en) Copper alloy cleaning process
GB1207326A (en) Preparation of tea
GB1289693A (en)
US2959520A (en) Stabilized aqueous solution of vitamin b complex containing cyanocobalamin and thiocyanates
GB889769A (en) Slowly acting insulin preparation in crystalline form
GB1488807A (en) Agents for the selective combating of weeds
GB929220A (en) Gold plating
GB1336609A (en) Antismoking preparation
ES464642A1 (en) Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulphamyl-benzolc acid and process for their manufacture
GB594355A (en) Improvements in or relating to silver solder alloys
GB1492106A (en) Gelatine dessert composition
GB751425A (en) Manufacture of injectable insulin preparations with protracted effect
GB812575A (en) Improvements in or relating to sweetening compositions and method for making same
GB708888A (en) Improved process for producing injectable insulin preparations with protracted effect
GB786768A (en) Aqueous zinc-tin alloy electroplating bath
ES436398A1 (en) Insulin preparations having antidiabetic activity and process for their manufacture